{"id":"NCT01590758","sponsor":"Dipexium Pharmaceuticals, Inc.","briefTitle":"Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers","officialTitle":"A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-06","primaryCompletion":"2016-08","completion":"2016-08","firstPosted":"2012-05-03","resultsPosted":"2017-06-14","lastUpdate":"2017-06-14"},"enrollment":189,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Foot Infection"],"interventions":[{"type":"DRUG","name":"Topical pexiganan cream 0.8%","otherNames":["MSI-78"]},{"type":"DRUG","name":"Topical placebo cream","otherNames":[]},{"type":"OTHER","name":"Standard wound care","otherNames":[]}],"arms":[{"label":"Topical placebo control","type":"PLACEBO_COMPARATOR"},{"label":"Topical pexiganan cream 0.8%","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to establish the clinical superiority and the safety of topical pexiganan cream 0.8% plus standard local wound care, as compared to placebo cream plus standard local wound care, in the treatment of mildly infected diabetic foot ulcers.","primaryOutcome":{"measure":"Number of Participants With Clinical Response","timeFrame":"28 days","effectByArm":[{"arm":"Topical Pexiganan Cream 0.8%","deltaMin":43,"sd":null},{"arm":"Topical Placebo Control","deltaMin":63,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":30,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":85},"commonTop":["Osteomyelitis","Skin ulcer","Cellulitis"]}}